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Abstract 
Enzymes in nucleotide metabolism serve as the producers of the building blocks for 
DNA and RNA. From a medical perspective, nucleotide metabolism, and in 
particular salvage pathway enzymes, have attracted special interest, as nucleoside 
prodrugs given in the treatment of cancer and HIV are converted into their active 
metabolite forms by these enzymes.  
In this thesis, two enzymes; uridine monophosphate kinase (UMPK) from 
Ureaplasma parvum  (Up)  and human phosphoribosyltransferase  domain containing 
protein 1 (PRTFDC1), have been investigated. Furthermore, a nucleoside analog 
library (NAL) consisting of 45 FDA-approved nucleoside analogs has been 
developed. 
The structure of Up-UMPK revealed that it was a hexamer. Kinetic constants 
were determined for UMP and ATP. UTP was a competitive inhibitor of UMP, 
and a non-competitive inhibitor of ATP. In contrast to other bacterial UMPKs, Up-
UMPK was not activated by GTP.  
PRTFDC1 is a homolog of hypoxanthine-guanine  phosphoribosyltransferase 
(HPRT). Mutations in HPRT are associated with Lesch-Nyhan syndrome. The 
three-dimensional structures of PRTFDC1 and HRPT are very similar. Even 
though PRTFDC1 recognizes guanine and hypoxanthine as substrates, the 
functional turnover rates are less than 1% of the activity of HPRT.   
NAL was screened using the high-throughput method, differential static light 
scattering (DSLS). An interaction profile of 23 enzymes involved in nucleotide 
metabolism and NAL was revealed. Interactions were detected for uridine 
phosphorylase 1 (UPP1) and guanine deaminase (GDA) with eight and six 
nucleoside prodrugs, respectively. The knowledge gained from this study can be 
important in the future search for drug lead candidates for UPP1 and GDA.  
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Abbreviations 
Nucleobases 
A           Adenine 
C           Cytosine 
G           Guanine 
Hx          Hypoxanthine 
T           Thymine 
U           Uracil 
X           Xanthine 
 
Nucleosides 
Ado         Adenosine  
dAdo       Deoxyadenosine 
Cyd         Cytidine 
dCyd       Deoxycytidine 
Guo          Guanosine 
dGuo       Deoxyguanosine 
Ino          Inosine 
dIno        Deoxyinosine 
Urd         Uridine 
dUrd        Deoxyuridine 
Thd         Thymidine 
 
Nucleotides 
dNMP      Deoxynucleoside monophosphate 
dNDP      Deoxynucleoside diphosphate 
dNTP        Deoxynucleoside triphosphate 
NMP       Nucleoside monophosphate 
NDP        Nucleoside diphosphate  
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NTP        Nucleoside triphosphate 
 
Other abbreviations 
AIDS       Acquired immune deficiency syndrome 
AlFx         Aluminofluoride  
BeFx        Beryllofluoride 
CMV       Cytomegalovirus 
CNT       Concentrative nucleoside transporter 
DSLS         Differential static light scattering 
ENT        Equilibrative nucleoside transporter 
FDA        U.S. Food and Drug Administration 
HIV          Human immunodeficiency virus 
HSV1       Herpes simplex virus type 1 
HSV2       Herpes simples virus type 2 
KEGG      Kyoto Encyclopedia of Genes and Genomes 
MDS       Mitochondrial DNA depletion syndrome 
MNGIE    Mitochondrial neurogastrointestinal encephalomyopathy 
MRP       Multidrug resistance proteins 
mtDNA      Mitochondrial DNA 
MTHF      5,10-methylenetetrahydrofolate 
NA         Nucleoside analog 
NAL        Nucleoside analog library 
NAMP     Nucleoside analog monophosphate 
NADP      Nucleoside analog diphosphate 
NATP      Nucleoside analog triphosphate 
NRTI      Nucleoside reverse transcriptase inhibitor 
NtRTI      Nucleotide reverse transcriptase inhibitor 
OAT       Organic anion transporter 
PEPT       Peptide transporter 
PDB        Protein data bank 
PPi          Pyrophosphate 
PRPP       Phosphoribosyl pyrophosphate 
SCID       Severe combined immunodeficiency 
SGC        Structural genomics consortium 
Tagg          Aggregation temperature 
UMPK     Uridine monophoshate kinase 
Up          Ureaplasma parvum 
VZV        Varicella zoster virus  
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Gene name  Other name  Protein name  
De novo synthesis of purines 
ADSL     Adenylosuccinate lyase 
ADSS, ADSSL1, ADSS2     Adenylosuccinate synthetase 
ATIC     Phosphoribosylaminoimidazole-
carboxamide formyltranseferase/ 
IMP cyclohydrolase  
GART     Phosphoribosylglycinamide 
formyltransferase,  
Phosphoribosylamine--glycine ligase, 
Phosphoribosylformylglycinamidine 
cyclo-ligase  
GMPS     GMP synthetase 
IMPDH1, IMPDH2  IMP dehydrogenase  Inosine 5’-monophosphate 
dehydrogenase 
PAICS     Phosphoribosylaminoimidazole 
carboxylase, 
Phosphoribosylaminoimidazole 
-succinocarboxamide synthetase 
PFAS     Phosphoribosylformylglycinamidine 
synthetase 
PPAT     Amidophosphoribosyltransferase 
De novo synthesis of pyrimidines 
CAD  Carbamoyl-phosphate 
synthetase 2 
Glutamine-dependent carbamoyl-
phosphate synthetase,  
Aspartate carbamoyltransferase, 
Dihydroorotase  
CTPS, CTPS2     CTP synthetase 
DCTD  dCMP deaminase   Deoxycytidylate deaminase 
DHODH     Dihydroorotate dehydrogenase, 
mitochondrial 
TYMS  TS, ThyA  Thymidylate synthase 
UMPS  UMP synthase  Uridine 5’-monophosphate synthase 
Ribonucleotide reductase 
RRM1, RRM2, RRM2B  RR  Ribonucleotide reductase 
RRM1  R1  Ribonucleoside-diphosphate reductase 
large subunit 
RRM2  R2  Ribonucleoside-diphosphate reductase 
small subunit 
RRM2B  P53R2  p53 inducible ribonucleotide reductase 
small subunit 2-like protein  
Salvage pathway  
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ADK     Adenosine kinase 
APRT     Adenine phosphoribosyltransferase 
DCK  dCK  Deoxycytidine kinase 
DGUOK  dGK  Deoxyguanosine kinase, mitochondrial 
HPRT1  HPRT  Hypoxanthine-guanine 
phosphoribosyltransferase 
PRTFDC1     Phosphoribosyltransferase domain 
containing protein 1 
TK1  TK1  Thymidine kinase 1, cytosolic 
TK2  TK2  Thymidine kinase 2, mitochondrial 
UCK1, UCK2     Uridine-cytidine kinase 
Mono- and diphosphate kinases 
AK1, AK2, AK3, AK4, AK5, 
AK7 
AMPK  Adenylate kinases 
DTYMK  TMPK  Thymidylate kinase 
GUK1  GMPK  Guanylate kinase 
NME1, NME2, NME3, 
NME4, NME5, NME6, 
NME7, NME1-2 
NDPK  Nucleoside diphosphate kinase 
CMPK1, CMPK2  UMP-CMPK  UMP-CMP kinase 
Catabolism of purines and pyrimidines 
ADA     Adenosine deaminase 
AMPD1, AMPD2, AMPD3 
CDA 
   AMP deaminase 
Cytidine deaminase 
DPYD     Dihydropyrimidine dehydrogenase 
[NADP
+] 
DPYS     Dihydropyrimidinase 
DUT  dUTPase   Deoxyuridine 5’-triphosphate 
nucleotidohydrolase 
GDA     Guanine deaminase 
GMPR, GMPR2 
ITPA 
 
ITPase  
GMP reductase 
Inosine triphosphate pyrophosphatase 
NUDT16  (deoxy)inosine 
diphosphatase 
U8 snoRNA-decapping enzyme 
PNP     Purine nucleoside phoshorylase 
TYMP     Thymidine phosphorylase 
UPB1     Beta-ureidopropionase 
UPP1, UPP2     Uridine phosphorylase 
XDH  Xanthine oxidase   Xanthine dehydrogenase/oxidase 
NT5C2, NT5C, NT5E, 
NT5C3, NT5M, NT5C1A, 
NT5C1B 
5'-nucleotidase   Purine   
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1  Introduction 
1.1  Enzymes in nucleotide metabolism 
Enzymes in nucleotide metabolism serve as the producers of the building 
blocks/precursors for DNA and RNA. An elaborate collection of enzymes 
are involved in producing a balanced deoxynucleotide pool, and are often 
regulated by sophisticated mechanisms. From a medical perspective, 
nucleotide metabolism,  and in particular salvage pathway enzymes, have 
gained special interest, as prodrugs given in the treatment of cancer and 
HIV are converted into their active metabolite forms by these enzymes.    
1.1.1  Synthesis of precursors for DNA and RNA 
Nucleotides are the building blocks of  DNA and RNA  and therefore 
essential for the ability of the cell to replicate, synthesize proteins and repair 
DNA. The nucleotides are divided into purine and pyrimidine nucleotides. 
”Nucleotide” is a general term for a structure comprised of a base, a pentose 
sugar and one to three phosphate groups. The purine nucleobases are 
adenine (A) and guanine (G), and the pyrimidine nucleobases are cytosine 
(C), thymine (T) and uracil (U). Thymine is only found in DNA and uracil 
is only found in RNA. The pentose sugar is either a ribose, which is found 
in RNA or 2’-deoxyribose, which is found in DNA (Figure 1).  
 
A nucleoside is comprised of a base with an added  pentose  sugar  but 
without any phosphate groups.  
 
Enzymes involved in nucleotide synthesis can make precursors via either 
de novo or salvage pathways. In the de novo pathway, nucleotides are built 
from  amino acids (aspartic acid, glycine and glutamine), CO2,  
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phosphoribosyl pyrophosphate (PRPP) and 5,10-methylenetetrahydrofolate 
(MTHF). Enzymes involved in the salvage pathway can recycle nucleobases, 
nucleosides and deoxynucleosides  obtained from either  degradation of 
RNA and DNA or from the diet.  
 
 
Figure  1.  Nucleobases, pentose sugars and one nucleotide. Nucleobases are grouped into 
purines (adenine and guanine) and pyrimidines (cytosine, uracil and thymine). The pentose 
sugars are ribose and 2’-deoxyribose.  An  example of a nucleotide, deoxycytidine 
monophosphate (dCMP), is also shown. 
Nucleotides are also important in other cellular functions, such as an 
energy currency (ATP and, to a lesser extent, GTP), as carriers of activated 
intermediates (UDP-glucose and CDP-diacylglycerol), as second messengers 
in signal transduction pathways (cAMP and cGMP) and as components of 
cofactors (Coenzyme A, FAD, NAD
+  and NADP
+). Furthermore, some  
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nucleosides and nucleotides  can act as extracellular signalling molecules 
(Burnstock, 2008). 
 
In the following sections, the reaction pathways leading to the synthesis 
of nucleotides are described. For simplicity, two figures are shown; Figure 2 
is an overview of purine metabolism and Figure 3 illustrates pyrimidine 
metabolism. Each reaction is labeled with a number corresponding to the 
enzyme(s) performing the reaction. The gene name in humans can be found 
in the figure text, in which the enzymes will be annotated by their gene 
names if not otherwise stated. 
1.1.2  De novo synthesis of purines 
In the  de novo  pathway,  AMP and GMP are  synthesized  via the 
intermediate, IMP. An activated pentose sugar, PRPP, serves as a starting 
point, and in a ten step reaction, IMP is generated from glutamine, glycine, 
aspartate, CO2 and MTHF. These reactions are carried out by six enzymes 
in  humans;  three monofunctional  enzymes  (PPAT, PFAS, ADSL), two 
bifunctional  enzymes  (PAICS and ATIC)  and one trifunctional  enzyme 
(GART).  Once IMP is synthesized, it can be converted into either AMP 
or GMP in two-step reactions by adenylosuccinate synthetase and ADSL for 
AMP, and IMP dehydrogenase and GMPS for GMP. A highly regulated 
step in de novo synthesis of purines is the first step leading to the generation 
of IMP  by the enzyme, amidophosphoribosyltransferase  (PPAT). This 
enzyme is inhibited by AMP, GMP and IMP and activated by PRPP 
(Welin & Nordlund, 2010; Zhang et al., 2008; Smith, 1995).  
1.1.3  De novo synthesis of pyrimidines 
In humans, the biosynthesis of UMP involves three enzymes; a trifunctional 
enzyme  (CAD), dihydroorotate dehydrogenase (DHODH) and a 
bifunctional enzyme (UMP synthase (UMPS)). The three domains of CAD 
(Carbamoylphosphate  synthetase  2,  Aspartate  carbamoyltransferase  and 
Dihydroorotase) assemble a six membered ring from glutamine, aspartic acid 
and CO2. PRPP is added through  the orotate phosphoribosyltransferase 
domain of UMPS. In order to produce CTP, UMP is phosphorylated by 
monophosphate  and diphosphate kinases  to UTP. UTP,  in  turn,  is 
aminated by CTP synthetase (CTPS and CTPS2) to CTP. Regulation of de 
novo pyrimidine synthesis is exerted on the carbamoylphosphate synthetase 
domain of CAD by UTP as a feedback inhibitor and PRPP as an activator. 
CTP synthetase is inhibited by the end product, CTP, and activated by 
GTP. Together, these regulatory mechanisms contribute to maintaining a  
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balanced production  of purine and pyrimidine nucleotides  (Welin & 
Nordlund, 2010; Evans & Guy, 2004).  
Production of dTTP is comprised of several steps; dCMP is converted 
into dUMP by dCMP deaminase (DCTD), followed by conversion of 
dUMP into dTMP by thymidylate synthase (TYMS), often referred to as 
TS or ThyA (Costi, 1998). 
1.1.4  Ribonucleotide reductase 
Ribonucleotide reductase (RR) is an important de novo enzyme, involved in 
the allosteric regulation of dNTP levels. RR catalyzes the conversion of the 
2’-OH of a ribonucleoside diphosphate to a hydrogen atom, generating a 
2’-deoxynucleoside diphosphate, through free radical chemistry. RR can be 
categorized into three different classes; I, II and III. In eukaryotes, class Ia is 
found. This form of RR is composed of  R1 and  one of the two  R2 
subunits (R2 or its homolog p53R2). The R1 subunit contains the catalytic 
site, the activity site and the specificity site. ATP is an activator and binds to 
the activity site, whereas dATP is an inhibitor. ATP, dATP, dTTP and 
dGTP function as effector molecules altering the substrate specificity 
depending on which molecule binds to the specificity site. The substrate 
molecules are CDP, UDP, ADP and GDP (Nordlund & Reichard, 2006; 
Reichard, 2002). The R2 subunit undergoes cell cycle-dependent 
degradation. p53R2, important in DNA repair, is expressed at a low level 
throughout the cell cycle, and is over expressed after DNA damage 
(Nordlund & Reichard, 2006).  
1.1.5  The salvage pathway 
Nucleobases, nucleosides and deoxynucleosides obtained from either 
degraded DNA or RNA or from the diet, can be recycled via reactions 
catalyzed by different families of enzymes. One family is the 
phosphoribosyltransferases, which includes adenine and hypoxanthine-
guanine phosphoribosyltransferase (APRT and HPRT1, in this work called 
HPRT)  (Sinha  & Smith, 2001). HPRT is the most well characterized 
member, as mutations in this enzyme are linked to Lesch-Nyhan syndrome. 
APRT recycles adenine, producing AMP, and HPRT can use both guanine 
and hypoxanthine as substrates in the synthesis of GMP and IMP. Both 
enzymes are expressed ubiquitously (Keough et al., 1999; Thomas et al., 
1973). A homolog of HPRT, phosphoribosyltransferase domain containing 
protein 1 (PRTFDC1) (Nicklas, 2006), is discussed in more detail in 
Chapter 3 and Paper II.  
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The deoxynucleoside kinases include thymidine kinase 1 or TK1 (TK1), 
deoxycytidine kinase or dCK (DCK), thymidine kinase 2 or TK2 (TK2) 
and deoxyguanosine kinase or dGK (DGUOK). These are the salvage 
enzymes used for recycling thymidine (Thd), deoxycytidine (dCyd), 
deoxyuridine (dUrd), deoxyadenosine (dAdo) and deoxyguanosine (dGuo). 
The  deoxynucleosides are phosphorylated by nucleoside triphosphates 
(NTPs) at the 5´position to become deoxynucleoside  monophosphate 
(dNMP). This is believed to the rate-limiting step for the salvage of dNTPs 
(Arner & Eriksson, 1995). TK1 and dCK are both cytosolic proteins. TK1 
has narrow substrate specificity and phosphorylates only Thd and dUrd, 
while both pyrimidine and purines i.e. dCyd, dAdo and dGuo can act as 
substrates for dCK. Deoxycytidine kinase is discussed in more detail in 4.4. 
Both TK2 and dGK are mitochondrial enzymes. TK2 can phosphorylate 
Thd, dCyd and dUrd, while the substrates for dGK are dAdo, dGuo and 
deoxyinosine. Reactions carried out by deoxynucleoside kinases are feed-
back inhibited by their distal end products (dTTP, dCTP, dATP and 
dGTP) (Eriksson et al., 2002).  
 
Two kinds of nucleoside kinases are identified in humans. Van Rompay 
et al. (2001) characterized two recombinant uridine-cytidine kinases (UCK1 
and UCK2), and it was shown that both enzymes could phosphorylate Urd 
and Cyd in the presence of ATP (Van Rompay et al., 2001). The other 
nucleoside kinase is an adenosine kinase (ADK), phosphorylating Ado into 
AMP (Spychala et al., 1996).  
1.1.6  Monophosphate kinases and nucleoside diphosphate kinase 
Once the nucleoside or deoxynucleoside monophosphates are made, they 
are phosphorylated further by their corresponding monophosphate kinase 
and nucleoside diphosphate kinase into final products, either NTPs or 
dNTPs. 
There are four categories of monophosphate kinases: thymidylate kinases 
or TMPK (DTYMK),  UMP-CMP kinases or UMP-CMPK  (CMPK1, 
CMPK2), adenylate kinases or AMPKs (AK1, AK2, AK3, AK4, AK5, AK7) 
and guanylate kinases or GMPK (GUK1). TMPK phosphorylates both 
dTMP and dUMP (Huang et al., 1994). 
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Figure 2. A simplified overview of purine metabolism including the de novo pathway (purple), 
the salvage pathway (green), the de novo and salvage pathway (blue) and the catabolic (red) 
pathway. The map is based on purine metabolism in humans  obtained from  Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et al., 2010; Kanehisa et al., 2006; 
Kanehisa & Goto, 2000). All enzymes annotated in italics have been investigated in Paper  
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III. For simplicity, reactions are shown progressing only in the most favored direction.  Each 
reaction  is given a number that  correlates to the following gene names.  If a protein is 
encoded by several genes, a common name for the protein is given: 1 PPAT, 2 GART, 3 
GART,  4  PFAS,  5  GART,  6  PAICS,  7  PAICS,  8  ADSL,  9  ATIC,  10  ATIC,  11 
Adenylosuccinate synthetase  (ADSSL1,  ADSS,  ADSS2)  12  ADSL,  13  IMP dehydrogenase 
(IMPDH1 or IMPDH2), 14 GMPS, 15 GMP reductase (GMPR and GMPR2), 16 AMP 
deaminase  (AMPD1, AMPD2, AMPD3),  17  Adenylate kinase  (AK1, AK2, AK4, AK5, 
AK7), 18 Nucleoside diphosphate kinase (NME1, NME2, NME3, NME4, NME5, NME6, 
NME7, NME1-2), 19 GUK1, 20 Ribonucleotide reductase (RRM1, RRM2, RRM2B), 21 5’-
Nucleotidase (NT5C2, NT5C, NT5E, NT5C3, NT5M, NT5C1A, NT5C1B), 22 ADK , 23 
DGUOK, 24 DCK, 25 PNP, 26 HPRT1, 27 APRT, 28 ITPA, 29 ADA, 30 GDA, 31 
XDH, 32 NUDT16. 
UMP-CMPK phosphorylates CMP and UMP with ATP or dATP as 
preferred phosphate donors (Liou et al., 2002; Van Rompay et al., 1999). A 
mitochondrial UMP-CMPK2 was reported in 2008 by Xu et  al.  This 
enzyme phosphorylates dUMP, dCMP, UMP and CMP, with a preference 
for deoxynucleotides (Xu et al., 2008). AMPKs preferentially phosphorylate 
AMP, but some AMPKs can also phosphorylate dAMP (Van Rompay et al., 
2000). GMPK phosphorylates GMP and dGMP into their diphosphate 
forms (Brady et al., 1996). 
A new class of UMP kinases was identified in E. coli (Serina et al., 1995). 
The bacterial/archaeal UMP kinase is a member of the amino acid kinase 
family and is subject to sophisticated regulation. This will be further 
discussed in Chapter 2 and Paper I. 
The nucleoside diphosphate kinases (NDPKs) are ubiquitous enzymes 
and eight different kinds have been identified in humans (Lacombe et al., 
2000). NDPKs catalyze the transfer of a γ-phosphoryl group to a nucleoside 
diphosphate. The enzymes are promiscuous with regard to phosphate 
donors and acceptors (Janin & Deville-Bonne, 2002). Besides NDPKs, 
other enzymes, such as pyruvate kinase, have been shown to have NDPK-
like properties (Deville-Bonne et al., 2010). 
Although not shown in Figures 2 and 3, the actions of the 
monophosphate and diphosphate kinases are reversible (Van Rompay et al., 
2000).  
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Figure 3. A simplified overview of pyrimidine metabolism including the de novo pathway 
(purple),  the  salvage  pathway  (green),  the  de novo  and salvage pathway (blue)  and  the 
catabolic (red) pathway. The map is based on pyrimidine metabolism in humans obtained 
from KEGG  (Kanehisa  et al., 2010; Kanehisa  et al., 2006; Kanehisa & Goto, 2000). All 
enzymes annotated in italics have been investigated in Paper III. For simplicity, reactions are 
shown progressing only in the most favored direction.  Each reaction is given a number that 
correlates to gene names  listed in this text. If a protein is encoded by several genes, a  
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common name for the protein is given: 1 CAD, 2 CAD, 3 CAD, 4 DHODH, 5 UMPS, 6 
UMPS, 7 CMPK1 and CMPK2, 8 Nucleoside diphosphate kinase (NME1, NME2, NME3, 
NME4, NME5, NME6, NME7, NME1-2), 9 CTP synthetase (CTPS and CTPS2),  10 
Uridine-cytidine  kinase  (UCK1, UCK2), 11  UPP1  and  UPP2,  12  Ribonucleotide reductase 
(RRM1, RRM2, RRM2B), 13 CDA, 14 5’-Nucleotidase (NT5C2, NT5C, NT5E, NT5C3, 
NT5M, NT5C1A, NT5C1B),  15  DUT,  16  DCK,  17  DCTD,  18  TK1 and TK2, 19 
DTYMK, 20 TYMS, 21 TYMP, 22 DPYD, 23 DPYS, 24 UPB1. 
1.1.7  Catabolism of purines and pyrimidines 
Excessive purines and pyrimidines are degraded and secreted via the urine. 
Purines are degraded to xanthine (X) and then to urate by xanthine oxidase 
(XDH).  Preceding reactions  involve  5’-nuclotidases, purine nucleoside 
phosphorylase (PNP), guanine deaminase (GDA) and adenosine deaminase 
(ADA).  Pyrimidines are degraded  via uracil and thymine,  which are 
themselves degraded to β-alanine and 3-aminoisobutanoate, respectively, by 
DPYD, DPYS and UPB1.  Before uracil and thymine are formed, the 
nucleotides/nucleosides are degraded by 5’-nuclotidases, cytidine deaminase 
(CDA),  uridine phosphorylases  (UPP1 and UPP2) and thymidine 
phosphorylase (TYMP).    
The presence of 5’-nucleotidases are also important for the maintenance 
of  a balanced nucleotide pool. 5’-nucleotidases  dephosphorylate 
(deoxy)nucleoside    monophosphates into (deoxy)nucleosides  and free 
phosphate ions. There are seven kinds of 5’-nucleotidases with overlapping 
substrate specificities  and different tissue expression.  Cytosolic  NT5C2 
prefers IMP, dIMP, GMP, dGMP and XMP as substrates, whereas cytosolic 
NT5C3  only hydrolyzes pyrimidine monophosphates  (Hunsucker  et al., 
2005). Other enzymes important for the regulation of nucleotide pools are 
GMP reductases  and AMP deaminases, which are  responsible for the 
conversion of GMP and AMP back to IMP.  
A group of enzymes called house-cleaning NTPases are responsible for 
the elimination of potentially toxic by-products of nucleotide metabolism, 
such as dUTP and dITP. ITPase (ITPA) hydrolyses dITP, ITP and XTP 
into their monophosphate forms, and dUTPase (DUT) can hydrolyse 
dUTP  to dUMP  (Galperin  et al., 2006).  A human (deoxy)inosine 
diphosphatase (NUDT16) was recently identified by Iyama et al. (2010). 
This  enzyme    catalyzes the hydrolysis of dIDP and IDP as preferred 
substrates (Iyama et al., 2010).   
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1.2  dNTP pools within the cell  
1.2.1  Highly regulated dNTP pools within the cell 
High fidelity in the maintenance of dNTP pools is of utmost importance. 
This is regulated  at  the  allosteric  level  as well as  the transcriptional and 
posttranslational  levels,  as  asymmetries in the natural dNTP pools are 
known to give rise to increased mutagenesis (Mathews, 2006; Reichard, 
1988).  
Allosteric regulation is carried out by many enzymes in  nucleotide 
metabolism, such as ribonucleotide reductase, CTP synthetase and DCTD 
(Evans & Guy, 2004; Reichard, 1988).  At a transcriptional and 
posttranslational level, dNTP pools are regulated in proliferating cells via 
controlled cell cycle-dependent protein synthesis and protein degradation. 
Examples  of enzymes controlled in this manner include  TK1 and R2-
subunit from ribonucleotide reductase (Mathews, 2006). 
 
Mitochondrial DNA (mtDNA) replication takes place both during the 
cell cycle and in non-dividing cells. The mitochondrial dNTP pools are 
separated from the nuclear precursor dNTP pools by the mitochondrial 
inner membrane. Precursors for mitochondrial DNA replication or repair 
can either be imported from the cytosol in dividing cells, or synthesized by 
mitochondrial salvage enzymes in non-dividing cells (Mathews & Song, 
2007; Saada, 2004). 
1.2.2  Diseases associated with mutations in enzymes in nucleotide 
metabolism 
Several disorders are directly linked to congenital errors in  purine and 
pyrimidine metabolism, and are characterized by the presence of distorted 
dNTP pools. The abnormalities are often a result of point mutations in the 
corresponding genes.  
 
A  number of disorders associated with purine metabolism have been 
found. The most well known disease is Lesch-Nyhan syndrome, caused by 
mutations in HPRT. Depending on the  mutation,  either partial HPRT 
deficiency or Lesch-Nyhan syndrome will develop (see  3.2.2).  APRT 
deficiency leads to  renal stone disease in children. Adenosine deaminase 
(ADA) deficiency has been successfully treated with gene therapy. If 
untreated, the deficiency will give rise to severe combined immuno 
deficiency (SCID), and affected individuals normally die before the age of 
two. Purine nucleoside phosphorylase (PNP) deficiency also gives rise to  
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SCID. Xanthine oxidase (XDH) deficiency is characterized by 
hypouricemia and is  associated with renal complications. Mutations in 
ATIC and ADSL, both of which are involved in the de novo biosynthesis of 
purine, give rise to developmental delay and mental retardation, 
respectively. Mutations in AMP deaminase (AMPDH1) can cause pains and 
cramps in patients during exercise (Nyhan, 2005). 
 
Disorders  associated with  pyrimidine metabolism include  the  de novo 
enzyme, UMPS, causing orotic aciduria. The disease can be treated by daily 
doses of uridine (Nyhan, 2005). A rare deficiency, called Miller syndrome, 
is caused by mutations in the de novo enzyme, DHODH, and gives rise to 
craniofacial defects  (Ng  et al., 2010).  Mutations in  the  pyrimidine 
catabolizing  enzymes,  DPYD, DPYS and UPB1,  preventing correct 
degradation of thymine and uracil, cause clinical manifestations as seizures 
and mental retardation (Nyhan, 2005). 
 
Increased 5’-nucleotidase activity toward both purines and pyrimidines 
has been associated with developmental delay and seizures (Nyhan, 2005). 
  
The integrity of the mitochondrial dNTP pools is important for cell 
survival, as mitochondria are producers of cellular ATP. Point mutations in 
the two mitochondrial salvage enzymes, dGK and TK2, give  rise to 
mitochondrial  DNA depletion syndrome (MDS). Affected  individuals 
usually die in early childhood (Saada, 2004).  Mutations in cytosolic 
thymidine phosphorylase (TYMP) have been shown to be involved in 
mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), 
characterized by aberrations in mtDNA, including multiple deletions and 
depletion. Elevated levels of Thd  and dUrd  leads  to  increased  levels of 
dTTP in mitochondria, and may  thus  distort the mitochondrial dNTP 
pools (Saada, 2004).  
1.3  Nucleoside analogs (NAs) 
A brief overview of each nucleoside analog (NA) will be presented here, 
including an account of the mechanisms underlying the  activation of a 
prodrug into an active metabolite (import into the cell, activation of NAs 
and resistance mechanisms).  
In Chapter 4 and Paper III, development of a nucleoside analog library 
(NAL) screen, consisting of 45  FDA-approved  (U.S. Food and Drug 
Administration) compounds, has been described. The structures of all 45  
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NAs are shown in Figures 4 to 7, according to drug application; anti-cancer 
agents (Figure 4), anti-viral agents (Figures 5 and 6) and agents used in the 
treatment of other medical conditions (Figure 7).  
1.3.1  NAs used as anti-cancer agents 
In 1957, fluorouracil was discovered to have anti-tumor activity toward 
transplanted tumors in rats and mice (Heidelberger  et al., 1957). 
Fluorouracil can be grouped together with floxuridine and capecitabine, the 
latter being metabolized in the cell to floxuridine and fluorouracil. 
Fluoropyrimidines are used in the treatment of gastrointestinal, pancreatic, 
head and neck, renal,  skin, prostate, breast and colorectal cancers. 
Thiopurines, such as thioguanine and mercaptopurine, are used in the 
treatment of acute leukaemias. Cladribine and fludarabine are both 
deoxyadenosine derivates used in the treatment of different malignant 
disorders of the blood. Fludarabine is administered in 5’-monophosphate 
form and is dephosphorylated in the body before cellular uptake (Galmarini 
et al., 2002). Clofarabine is a next generation dAdo analog, approved by the 
FDA in 2004 for the treatment of pediatric leukemic patients (Zhenchuk et 
al., 2009). Cytarabine, a dCyd analog, is also used against hematological 
disorders of the blood, while gemcitabine, a dCyd analog, is active against 
solid tumours, such as pancreatic, breast, lung and bladder cancer (Galmarini 
et al., 2002). An additional four NAs approved by FDA are used in the 
treatment of cancer. These are nelarabine, azacitidine, decitabine and 
pemetrexed. 
1.3.2  NAs used in treatment of viral diseases 
Nucleoside analogs are used in the treatment or prophylaxis of several 
diseases caused by viruses such as HIV, herpes simplex virus type 1 and 2 
(HSV1, HSV2), Varicella zoster virus (VZV), cytomegalovirus (CMV), and 
hepatitis B and C viruses.  Herpes viruses do not constitute a risk in 
immunocompetent individuals, but in immunocompromised patients 
(AIDS, cancer and transplant patients), the different  herpes viruses can 
cause serious illness (Snoeck, 2000). 
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Figure 4. NAs used as anti-cancer agents.  
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Figure 5. NAs used in the treatment of HSV1, HSV2, VZV or CMV.  
Idoxuridine, trifluridine and vidarabine belong to the first generation 
NAs used in treatment of herpes viruses. These analogs are not specific for 
viral replication enzymes, and are too toxic for systemic use (De Clercq & 
Field, 2006; Kleymann, 2003). The second generation compounds used in 
the treatment of HSV1, HSV2, VZV and CMV, were introduced with the 
discovery of the acyclic NA, aciclovir in 1974, which entered the market in 
1981. The acyclic NAs are recognised by viral enzymes, and are therefore  
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specific for viral replication. Aciclovir has a limited oral availability and only 
some 20% is absorbed from the gastrointestinal tract. Great efforts have been 
made to develop the acyclic concept, and have lead to the development of 
valaciclovir, a prodrug for aciclovir, with greater oral availability. Other 
acyclic analogs are penciclovir, ganciclovir, famciclovir and valganciclovir 
(Pescovitz, 2010; De Clercq & Field, 2006; Pescovitz, 2006; Freeman & 
Gardiner, 1996). 
Cidofovir  is a nucleoside phosphonate used in treatment of CMV in 
AIDS patients (De Clercq & Field, 2006). 
 
Since HIV was identified as the etiological agent of AIDS in 1983, 
increasing knowledge of the virus and disease, has led to the discovery of 25 
approved anti-HIV compounds for the treatment of HIV and AIDS. Seven 
compounds (didanosine, zalcitabine, stavudine, lamivudine, abacavir, 
emtricitabine and zidovudine) are nucleoside reverse transcriptase inhibitors 
(NRTIs). Tenofovir is the only nucleotide reverse transcriptase inhibitor 
(NtRTI) that has been approved for clinical use against HIV and AIDS (De 
Clercq, 2009).  
Since 1998, five antiviral NAs (tenofovir, adefovir, lamivudine, 
telbivudine and entecavir) have been approved for the treatment of chronic 
hepatitis B (Yuen & Lai, 2011). Ribavirin is used in the treatment of 
chronic hepatitis C (Munir et al., 2010).  
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Figure 6. NAs used in the treatment of HIV, AIDS, hepatitis B and hepatitis C. Some NAs, 
such as tenofovir and lamivudine are used in the treatment of both HIV and hepatitis B. 
1.3.3  NAs in the treatment of other medical conditions 
Allopurinol is used in the treatment of gout and hyperuricemia (Ferreira, 
1965), whereas flucytosine is one of the “old” antifungal agents (Chen & 
Sorrell, 2007). From the early 1960s until the early 1980s, azathioprine was 
used as a first choice immune suppressor in combination with steroids after 
renal transplantation (Briggs, 1991).  
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Adenosine  is used in the  treatment of paroxysmal supraventricular 
tachycardia  (Muller & Jacobson, 2011). The xanthine derivates (caffeine, 
dyphylline, theophylline, theobromine, pentoxyfylline and enprofylline) all 
have  bronchodilator properties.  Theophylline  has  been  used  in  the 
treatment of asthma (Daly, 2007; Skorodin, 1993).  
 
Figure 7. NAs used in the treatment of other medical conditions.   
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1.3.4  Mechanisms responsible for activation of NAs 
Most of the NAs included in our NAL, with exception of the xanthine 
derivates, adenosine, allopurinol and pemetrexed, are prodrugs. In order to 
see an effect of an analog, it must be activated to an active substance within 
the cell. In this chapter, the mechanisms underlying nucleotide metabolism, 
especially via the salvage pathway, are described, with a focus on the NAs 
used as anti-cancer agents or in the treatment of viral diseases.  
 
The  first  step  in nucleoside  analog  action  is  import  into the cell. 
Transporter  systems include  equilibrative  nucleoside transporters (ENT), 
concentrative nucleoside transporters (CNT), organic anion transporters 
(OAT) and peptide transporters (PEPT). A group of multidrug resistance 
proteins (MRP), pumps controlling the reverse action of transporters, are 
also involved. The mechanisms the uptake of all NAs are not well known 
(Pastor-Anglada et al., 2005).  
Once inside the cell, the salvage nucleoside and deoxynucleoside kinases, 
dCK, TK1, TK2, dGK, ADK, UCK1 and UCK2, are responsible for the 
first phosphorylation of the NAs. The nucleoside analog monophosphates 
(NAMPs)  are phosphorylated further by monophosphate kinases into 
nucleoside analog diphosphate (NADP) forms, and thereafter by nucleoside 
diphosphate kinases into the corresponding nucleoside analog triphosphate 
(NATP) forms. The NATPs are incorporated into cellular DNA/RNA and 
viral DNA by either DNA polymerase (cellular or viral), RNA polymerase 
or viral reverse transcriptase  (Figure  8)  (Van Rompay  et al., 2003; Van 
Rompay et al., 2000). The intracellular pool of phosphorylated NAs, either 
in  mono, di or tri phosphate form, depends on the turnover of  each 
intermediate. The rate-limiting step in the conversion of an NA can thus be 
either a monophosphate or diphosphate kinase (Deville-Bonne et al., 2010).  
The herpes viruses, HSV1, HSV2 and VZV, all possess a viral thymidine 
kinase  responsible for  activation of the NA. This  explains the low 
cytotoxicity  of the acyclic NAs (De Clercq & Field, 2006). The acyclic 
nucleoside phosphonate analogs (tenofovir, cidofovir and adefovir) are 
activated by the monophosphate kinases as a first step (Van Rompay et al., 
2000). Activation mechanisms of nucleobase analogs follow different routes. 
Flucytosine, for example,  is converted into fluorouracil by a unique 
cytosine deaminase found only in fungi and bacteria (Aghi et al., 2000). 
One activation mechanism for fluorouracil has been suggested to proceed 
via UPP1 (Cao et al., 2002). The thiopurines can be activated into their 
monophosphate forms by HPRT (Coulthard & Hogarth, 2005).   
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Figure 8. Activation of NAs through the salvage pathway. The NAs are imported via the 
action of different transporters (ENT, CNT, OAT, PEPT) and exported via MPR. The 
NAs are activated via viral or cellular (d)NKs, cellular NMPKs and cellular NDPKs. The 
phosphorylated NAs, in turn, can inhibit or interact with other enzymes involved in 
nucleotide metabolism. The triphosphate form can inhibit viral DNA replication or cellular 
DNA replication and DNA repair (Modified from Van Rompay et al., 2000). 
The activated NAs can exert their growth inhibiting effect at several 
levels. For example, (1) NAMPs can inhibit cellular enzymes, such as TS, 
(2) NADPs and NATPs can inhibit cellular enzymes, such as RR, and (3) 
NATPs can inhibit  either viral DNA replication or cellular DNA 
replication and repair or inhibit cellular enzymes (Figure 8) (Van Rompay et 
al., 2000). 
A few examples of  inhibitory effects may  be given to illustrate the 
complexity in the functions of individual NAs.  
 
Fluorouracil, for example, is activated to FdUMP within the cell, and 
this intermediate can then  react with TS, forming a covalent bond, 
inactivating the enzyme and leading to depletion of the dTTP pools 
(Friedman & Sadee, 1978).  
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Gemcitabine diphosphate inhibits RR, thus blocking the de novo 
synthesis of dNTPs and altering the ratio between gemcitabine triphosphate 
and dNTPs, favouring incorporation of the analog into DNA (Galmarini et 
al., 2001).  
 
Incorporation of an  NATP into the growing DNA strand can cause 
chain termination. Dideoxynucleosides, such as zalcitabine, operate in this 
manner  (De Clercq, 2009).  In non-dividing cells, the incorporation of 
cladribine triphosphate into a DNA strand inhibits  the DNA repair 
machinery and accumulation of single stranded DNA breaks can potentially 
initiate apoptosis (Galmarini et al., 2001).  
1.3.5  Resistance towards NAs 
An emerging problem in patients treated with NAs is resistance to these 
compounds. Resistance occurs at several levels, and is probably a 
combination of multiple factors. Several potential resistance mechanisms are 
discussed below. 
 
Uptake of NAs via membrane transporters can be affected, thereby 
lowering the intracellular concentration of the NAs (Galmarini et al., 2001). 
Increased activity of 5’-nucleotidases has been correlated with lower overall 
survival for patients with haematological malignancies (Galmarini  et al., 
2001). A raised level of CDA has been suggested to increase the metabolism 
of  NAs within the cells, thereby lowering the concentration of active 
metabolites  (Galmarini  et al., 2001). Finally, up-regulated levels of the 
dNTP pools have been observed in many tumor cells, which restrict the 
incorporation of NATPs into the growing DNA strand (Galmarini et al., 
2001; Traut, 1994).   
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1.4  Mollicutes as a model organism for the salvage pathway? 
A uridine monophosphate kinase from Ureaplasma parvum (Up) is described 
in Chapter 2 and Paper I. Up belongs to the class of bacteria known as 
Mollicutes.  
1.4.1  Mollicutes  
Mollicutes belong to the kingdom of bacteria, and are often referred to as 
mycoplasma. A unique property of this class is that they have no cell wall. 
This also explains the name of the class, which literally means soft skin 
(mollis = soft and cutis = skin). Another characteristic trait is the minute 
size of the genomes; the smallest genome reported is only 580 kb and 
belongs to Mycoplasma genitalium and the larger genomes are up to 2200 kb 
long (Razin et al., 1998). The genome of Up serovar 3 is 751.7 kb, and the 
G+C content is 25.5% (Glass et al., 2000). This makes the Mollicutes ideal 
for studying the minimal set-up of genes required for maintenance of life 
processes (Razin et al., 1998). 
Sequencing of complete genomes from M. genitalium, M. pneumoniae and 
Up in 1995, 1996 and 2000, respectively, revealed that these bacteria have 
no genes for the de novo synthesis of purines and pyrimidines (Glass et al., 
2000; Himmelreich et al., 1996; Mushegian & Koonin, 1996; Fraser et al., 
1995). In order to survive, precursors for RNA and DNA synthesis must be 
imported from the surroundings and anabolized via salvage pathways and 
monophosphate kinases into their final products.  
Among  the  mollicute species, some are known to be disease causing 
agents, while others are viewed as commensal i.e. the bacteria benefit from 
living in symbiosis with humans without harming the individual. In recent 
decades,  several  mollicute species have  been isolated from 
immunocompromised individuals. Mollicutes are thus listed as opportunistic 
pathogens (Waites et al., 2005). This highlights the importance of finding 
new antibiotics toward  the different mollicute species.  Chapter 2 and 
Paper I describe attempts to characterize a potential drug target from Up.  
1.4.2  Ureaplasma parvum  
Up is a human opportunistic pathogen found in the urogenital tract. It is 
referred to as part of the commensal system in the female genital tract, as it 
is found in 40% of sexually inactive and 67% of sexually active women. 
Infection with Up has been associated with male urethritis and prostatitis 
(Volgmann et al., 2005). Up can cause several obstetrical complications such  
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as spontaneous abortions, low birth weight and infertility. The bacteria can 
be transferred vertically from mother to child, either through intrauterine 
infection or passage through the birth canal. In full-term neonates, Up does 
not constitute a great risk. However,  for premature neonates, especially 
those of birth weights less than 1500 g, infection of Up has been directly 
linked to bacteraemia,  congenital and neonatal pneumoniae and 
development of bronchopulmonary dysplasia (Sung, 2010; Volgmann et al., 
2005). 
Up has no cell wall and is thus not affected by beta-lactam antibiotics. 
Instead, antibiotics that interfere with protein synthesis, such as macrolides 
and tetracyclines, are used to treat Up infections (Waites et al., 2005). Only 
macrolides are considered for the treatment of neonatal Up-infections, due 
to the side effects of tetracyclines (Sung, 2010; Volgmann et al., 2005).  
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2  Uridine monophosphate kinase from 
Ureaplasma parvum (Paper I) 
2.1  Aim of the study 
The uridine monophosphate kinase (UMPK) from Up has been investigated 
because it was found to be a potential drug target in the development of 
new antibiotics against  Up-infections.  Up-UMPK fulfils two important 
criteria for choosing this enzyme as a drug target; first of all, Up relies on 
the salvage pathway and monophosphate enzymes in order to survive, and 
secondly,  Up-UMPK belongs to the amino acid kinase family,  while its 
human counterpart,  UMP-CMPK,  belongs to the nucleoside 
monophosphate kinase family.  
2.2  Bacterial and archaeal UMPKs 
UMPK catalyzes the reversible phosphorylation of UMP, using ATP as a 
phosphate donor (Serina et al., 1995). The protein is encoded by the PyrH 
gene which has been identified in many bacteria and archaea (Labesse et al., 
2010; Lee et al., 2010; Tu et al., 2009; Meier et al., 2008; Egeblad-Welin et 
al., 2007; Evrin et al., 2007; Jensen et al., 2007; Marco-Marin et al., 2005; 
Fassy et al., 2004; Gagyi et al., 2003; Serina et al., 1995). The PyrH gene has 
been shown to be essential for the survival of E. coli, H. influenzae and St. 
pneumoniae (Fassy et al., 2004; Akerley et al., 2002; Yamanaka et al., 1992). 
In general,  the bacterial UMPKs are hexamers, and  they are subject to 
allosteric regulation via activation by GTP and inhibition by the distal end-
product, UTP (Lee et al., 2010; Evrin et al., 2007; Gagyi et al., 2003; Serina 
et al., 1995).  A group of UMPKs from gram-positive bacteria exhibited 
positive cooperativity with ATP as a substrate (Evrin et al., 2007; Fassy et  
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al., 2004). An interesting feature is that UMPKs from Up and the archaea, 
Sulfolobus solfataricus, are not activated by GTP (Egeblad-Welin et al., 2007; 
Jensen et al., 2007). Phosphoryl transfer for UMPK in S. solfataricus has been 
suggested to follow a sequential random bi-bi reaction mechanism (Jensen et 
al., 2007). UMP kinase within the cell is located close to the membrane in 
B. subtilis and E. coli (Gagyi et al., 2004; Landais et al., 1999). Furthermore, 
UMPK from E. coli has been suggested to act as a sensor in regulation of the 
internal pyrimidine nucleotide pools. A high level of nucleotides can thus 
serve as a signal for repression of the enzyme responsible for the first step in 
de novo pyrimidine synthesis (Kholti et al., 1998). 
The first structure of a bacterial UMPK was demonstrated using Neisseria 
meningitidis  (Protein data bank (PDB)  id: 1YBD). The  structure  was 
deposited in the protein data bank in February 2005. This was followed by 
structures of UMPKs from E. coli and Pyrococcus furiosus published in 2005, 
revealing an enzyme belonging to the amino acid kinase family, and with 
similarities to carbamate kinase and N-acetylglutamate kinase (Briozzo et al., 
2005; Marco-Marin et al., 2005). Today, the structures of bacterial UMPKs 
from 11 different organisms, in complex with substrates,  allosteric 
regulators and/or apo-structures, have been solved (Labesse et al., 2010; Tu 
et al., 2009; Meier et al., 2008; Meyer et al., 2008; Egeblad-Welin et al., 
2007; Jensen et al., 2007; Briozzo et al., 2005; Marco-Marin et al., 2005). 
Four of the UMPK structures have been deposited in the protein data bank 
but not yet published (PDB-id’s: 2IJ9, 2AIF, 1Z9D and 1YBD).  The 
structures have revealed three binding sites: one site for UMP and one for 
ATP in the active site, and an allosteric site for GTP.  
2.3  Kinetics 
The kinetic constants were determined for the interactions between Up-
UMPK and its two substrates, UMP and ATP. The primary plot of the 
two-substrate kinetic experiments indicates that the reaction mechanism is 
sequential. Km(UMP) was 214 ± 4 µM, K0.5(ATP) was 316 ± 54 µM and 
Vmax was 262 ± 24 µmol⋅min
-1⋅mg
-1. 
The nature of the inhibition patterns of UTP toward UMP and ATP 
was investigated, and showed that UTP was a competitive inhibitor of 
UMP, which is in accordance with structures from E. coli in complex with 
both UMP and UTP. In these structures, it is clear that UTP binds within 
the active site, with the uracil base in the same position  as for UMP 
(Briozzo et al., 2005). UTP acts as a non-competitive inhibitor of ATP, 
leading to a decrease in Vmax, while Km(ATP) remained at the same level.  
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The Ki values for UTP as an inhibitor of UMP and ATP are 0.7 mM and 
1.2 mM, respectively. 
When GTP was tested as an allosteric activator, no effect was observed, 
and this was the first bacterial UMPK showing this behaviour. 
Altogether,  the  rate of Up-UMPK is most likely determined by the 
intracellular levels of UMP, as the enzyme is less sensitive to UTP feedback 
inhibition, and, in contrast to other bacterial UMPKs, is not activated by 
GTP. 
2.4  Structure of Up-UMPK 
Before  it became clear  that  Up-UMPK was not activated by GTP, the 
enzyme was crystallized in the presence of 5 mM GTP, and resulted in 
crystals diffracting to 2.5 Å. The structure was  solved by molecular 
replacement using the monomer of UMPK from H. influenzae (PDB id: 
2A1F). A phosphate ion was observed in the active site of each monomer, 
corresponding to the position of the β-phosphate of UDP and UTP when 
Up-UMPK was superimposed  on  E. coli  UMPK in complex with these 
nucleotides (PDB id’s: 2BND and 2BNF).  
The enzyme is a hexamer of  three dimers related by a three-fold 
symmetry  (Figure 9A). Each monomer has an α/β-fold with a nine-
stranded β-sheet surrounded by eight α-helices and one 310 helix (Figure 
9B). The primary contact between subunits A and B is predominantly via 
hydrophobic interactions between the two antiparallel α3  helices.  One 
interaction between subunits A and C is  via a hydrophobic interaction 
formed between amino acid residues T131 and F133 situated in a flexible 
loop (Figure 9C).  
2.5  Mutational study 
The structure of E. coli  revealed a cross-talk region, where  amino acid 
residues, T138 and N140 form two hydrogen bonds with the equivalent 
amino acid residues in the neighbouring  subunit. In Up-UMPK this 
interaction corresponds to the hydrophobic interactions between T131 and 
F133 between the A and C subunits (Figure 9C). Replacement of either 
residue with an alanine in E. coli UMPK, resulted in enzymes that were not 
activated by GTP (Briozzo et al., 2005). The cross-talk region in E. coli 
UMPK forms hydrogen bonds, while hydrophobic interactions are 
observed in Up-UMPK. We therefore suggested that the presence of an 
asparagine in position 140 in E. coli  is  involved in the GTP activation  
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mechanism. F133 was substituted with an alanine or an asparagine residue; 
however, neither  Up-UMPK-F133N  nor  Up-UMPK-F133A  were 
activated by GTP. Similar mutations were created in B. subtilis UMPK with 
substitution of the threonine and asparagine residues with alanine, however 
these mutated enzymes were still activated by GTP (Evrin et al., 2007). 
Altogether, these results show that the cross-talk region is not part of a 
“GTP activation” motif.  
 
Figure 9. Structure of Up-UMPK, A) Hexamer, B) Monomer, C) Subunit A, B and C. Two 
amino acid residues, T131 and F133, involved in hydrophobic interactions, are marked in 
red on subunits A and C. The protein structure figures were made using PyMOL (PyMOL 
© 2005, DeLano Scientific LLC, South San Francisco, California, U.S.A). 
2.6  Binding site for GTP 
The  allosteric site in UMPK responsible  for binding GTP was recently 
identified in four different  UMPKs from E. coli,  Bacillus anthracis,  
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Xanthomonas campestris and Mycobacterium tuberculosis (Labesse et al., 2010; Tu 
et al., 2009; Meier et al., 2008; Meyer et al., 2008). In order to illustrate the 
two very distinct binding sites, the binding of UMP and GTP is shown for 
E. coli (Figures 10A and 10B). The binding mode of GTP in E. coli UMPK 
differs from those of X. campestris UMPK and M. tuberculosis UMPK. In B. 
anthracis, an ATP molecule binds in the GTP allosteric site. The allosteric 
site is situated between two subunits from two dimers. In E. coli UMPK, 
the GTP molecule is more deeply buried, while it is located closer to the 
central cavity in the other three reported UMPKs. The allosteric site is 
found in a position that would correspond to the space between subunits B 
and C of Up-UMPK (Figure 9C). 
 
As suggested by Jensen et al. (2007), amino acid residues between the 
end of α-helix 3 and  β-strand 5  (i.e.  E. coli  UMPK numbering) are 
responsible for binding GTP. However, the particular amino acid residues 
involved in binding GTP depend on the structure under analysis (E. coli vs 
X. campestris) (Figure 10E). Attempts to uncover the corresponding residues 
in Up-UMPK have been based on both possible binding modes of GTP.  
When GTP is bound to E. coli UMPK (Figure 10C), several amino acid 
residues from position 92 to 130 were  shown  to be involved in  GTP-
binding  (Meyer  et al., 2008). Several arginines (R92, R103, R127 and 
R130) were found in this region, and were shown to interact with GTP. 
None of these arginines were found in Up-UMPK. Marco-Marín & Rubio 
(2009) performed site-directed mutagenesis of many of these residues, and 
showed that substitution  of R103 and R130 with  alanine completely 
abolished the ability of E. coli UMPK to be activated by GTP. The role of 
W119 is to stack against the guanine base of GTP; when this residue is 
substituted with  alanine,  GTP activation is abolished  (Marco-Marin & 
Rubio, 2009; Meyer et al., 2008). In Up-UMPK, the corresponding residue 
for W119 is A112, and it is therefore unable to stack to the base moiety of 
GTP. 
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Figure 10. A) E. Coli UMPK with UMP (orange) bound (PDB id: 2BNE) (Briozzo et al., 
2005). B) E. coli UMPK with GTP (yellow) bound (PDB id: 2V4Y) (Meyer et al., 2008). C) 
GTP binding site in E. coli UMPK  (Meyer et al., 2008), amino acid residues written in bold 
belong to E. coli, while amino acid residues in italic belong to the corresponding residues in 
Up-UMPK. D) GTP binding site in X. campestris  UMPK  (Tu  et al., 2009), amino acid 
residues written in bold belong to X. campestris, while amino acid residues in italic belong to 
the corresponding residues in Up-UMPK. E) Local alignment of residues between α-helix 3 
and β-strand 5 (of E. coli). Amino acid residues binding to GTP have been underlined in the 
alignment. The accession numbers for the sequences are; E. coli, P0A7E9; H. influenzae, 
P43890;  X. campestris, P59009; B. subtilis, O31749; B. anthracis, Q81S73; U. parvum, 
Q9PPX6; P. furiosus, Q8U122 and S. solfataricus, Q97ZE2. The alignment was made using 
Clustal W2 and ESPript 2.2 (Gouet et al., 1999).   
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Few interactions between the guanine base and UMPK are involved in 
GTP binding in X. campestris UMPK (Figure 10D). A number of arginines 
(R100, R117, R118, R121, R127) are found to interact with the ribose 
moiety and the phosphate groups but none of these arginine residues are 
found in Up-UMPK. 
 
The residues necessary for an allosteric site in Up-UMPK appear to have 
been lost, regardless of whether GTP binds in a manner similar to E. coli or 
X. campestris UMPK. The presence of the arginines appears to be essential 
for binding of GTP as an allosteric activator, yet none of these arginine 
residues are found in Up-UMPK. Three residues are conserved in GTP 
binding among UMPKs from E. coli and X. campestris and these are referred 
to with E. coli numbering: R103, S124 and R130. Among all the residues 
reported to interact with GTP, R103 and R130 seem to play pivotal roles. 
In Up-UMPK, the corresponding amino acid residues are I96 and Q123.   
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3  Human phosphoribosyltransferase 
domain containing protein 1, a homolog 
of HPRT (Paper II) 
3.1  Aim of the study 
This study was done in collaboration with the  Structural Genomics 
Consortium (SGC) at the Karolinska Institute, Stockholm (see also 4.1). In 
the present study,  the structure and function of human  PRTFDC1  was 
elucidated. PRTFDC1 is a homolog of HPRT with 65% sequence identity. 
HPRT has been extensively characterized;  mutations in this gene are 
responsible for partial or full HPRT deficiency, the latter associated with 
the complex neurological disease, Lesch-Nyhan syndrome (Torres & Puig, 
2007).  
3.2  Background 
3.2.1  HPRT 
HPRT  catalyzes the reversible reaction in which guanine/hypoxanthine 
(Hx)  and PRPP are converted to  GMP/IMP and PPi  (Craig & Eakin, 
2000). The forward reaction is suggested to be ordered and sequential, with 
PRPP being the first substrate to bind, followed by the nucleobase. The 
pyrophosphate is released prior to the nucleotide (Craig & Eakin, 2000). 
The enzyme is constitutively expressed in most tissues, although it is more 
abundant in the brain (Jiralerspong & Patel, 1996). The structure of human 
HPRT was solved by Eads et al. in 1994. The monomer consists of two 
domains: a core domain and a hood domain (Keough et al., 2005; Eads et  
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al., 1994). A flexible loop, known as loop II, has been shown to cover the 
active site when a transition state analog is bound to the enzyme (Shi et al., 
1999).  
Eleven amino acid residues around the active site are conserved among 
all genes encoding HPRTs. The residues in human HPRT are L67, G69, 
S103, Y104, E133, D134, D137, K165, G189, D193 and R199 (Craig & 
Eakin, 2000). Aspartate 137 has been suggested to act as a general base due 
to its proximity to N7  of the purine ring (Xu & Grubmeyer, 1998). 
However, a site-directed mutagenesis study on residue D137 of Trypanosoma 
cruzi  HPRT  suggested that its  function is to act as a transition state 
stabilizer, via a hydrogen bond to N7 of the purine ring, thereby promoting 
catalysis (Canyuk et al., 2001).  
 
The specific activity (Vmax  values) for recombinant HPRT have been 
reported to be 46 µmol⋅mg
-1⋅min
-1 and 27 µmol⋅mg
-1⋅min
-1 with G and Hx as 
substrates, respectively. The Km(app)-values at 1 mM PRPP were reported 
to be 1.9 ± 0.3 and 3.1 ± 0.9 with G and Hx as substrates, respectively 
(Keough et al., 1999). 
 
Measurement of HPRT activity 
The enzymatic activity of HPRT in forward reactions has been 
determined by several methods; a radiochemical assay using [
14C]-labeled 
substrates  and two variants of spectrophotometric assays (Keough  et al., 
1987; Giacomello & Salerno, 1977). Lately, the method of choice has been 
the spectrophotometric assay, where the amount of product is measured 
using a light source of a wavelength between 240 and 260 nm  (Keough et 
al., 1987). 
 
3.2.2  HPRT deficiencies  
Mutations in HPRT  have been associated with  partial  and  full HPRT 
deficiencies. More than 300 mutations in HPRT have been identified in 
patients, giving rise to primarily point mutations or truncated versions of 
the protein (Jinnah  et al., 2004; Jinnah  et al., 2000).  Partial HPRT 
deficiency has been associated with hyperuricemia, gout and potentially 
dystonia. Full HPRT deficiency is linked to Lesch-Nyhan syndrome. 
Dystonia, mental retardation and self-injurious behaviour are some of the 
traits characterizing this disease (Torres & Puig, 2007).  
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3.2.3  PRTFDC1 - a homolog of HPRT 
PRTFDC1  was identified as a homolog of  HPRT, when a search for 
pseudogenes of HPRT1  was  performed.  PRTFDC1  was found to be 
conserved in vertebrates, and it was therefore suggested that although it was 
likely to be a functional gene, that function was unknown (Nicklas, 2006). 
Keebaugh et al. (2007) suggested that proteins encoded by PRTFDC1 had 
lost their ancestral HPRT enzymatic activity. This hypothesis was based on 
the presence of 11 conserved residues in HPRT1, of which not all were 
conserved in PRTFDC1 (Keebaugh et al., 2007; Craig & Eakin, 2000). It 
was suggested that PRTFDC1  remained  in the genome and possibly 
evolved a new function (Keebaugh et al., 2007). 
Two recent studies have identified PRTFDC1  as a putative tumor 
suppressor gene potentially involved in the inhibition of the development of 
ovarian cancer and oral squamous-cell carcinomas (Cai et al., 2007; Suzuki 
et al., 2007). 
Furthermore, PRTFDC1 has been shown to interact with HPRT (Rual 
et al., 2005).  
3.3  Structure of PRTFDC1 
The structure of recombinant  PRTFDC1 was solved with GMP bound 
within the active site at 1.7 Å resolution. The monomer is comprised of the 
core and hood domains. The core domain contains a six-stranded, twisted 
parallel β-sheet surrounded by three α-helices. The hood domain consists 
primarily  of residues from the C-terminus, and is made up by a two-
stranded anti-parallel β-sheet, and one α-helix. The flexible loop, loop II, is 
stabilized by part of β4 and β5 (Figure 11).   
 
The structure of PRTFDC1 was superimposed on structures of human 
HPRT (PDB-ids: 1Z7G (ligand free), 1BZY (transition state analog) and 
1HMP (GMP)) (Keough et al., 2005; Shi et al., 1999; Eads et al., 1994). 
The rmsd values of the superimpositions varied between 1.0 and 1.7 for 
approximately 200 Cα atoms, thus showing that the structures of HPRT 
and PRTFDC1 are very similar.  
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Figure 11. Monomer of PRTFDC1 with GMP. 
3.4  Functional studies 
3.4.1  Metabolome library 
A differential static light scattering (DSLS) thermal-melt assay was used to 
investigate the function of PRTFDC1 (see 4.3). A nucleotide metabolome 
library containing 81 compounds (substrates, products, inhibitors, activators 
of nucleotide metabolism) was screened with PRTFDC1. Increased thermal 
shifts for PRTFDC1 in the presence of PRPP, IMP and GMP, indicated a 
function for PRTFDC1 similar to HPRT. However, thermal shifts for the 
nucleobases (Hx and G) alone were not observed. When PRPP was added, 
both Hx and G exhibited higher thermal shifts. This result supports the 
concept of an ordered sequential bi-bi mechanism, similar to that observed 
for HPRT  (Craig & Eakin, 2000).  This  suggests  that PRPP is the first  
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substrate to bind to PRTFDC1, followed by the nucleobase. In summary, 
the ligands found in this study, suggested that PRTFDC1 and HPRT fulfil 
similar functions. 
3.4.2  Kinetics 
A radiochemical assay with tritium-labeled nucleobases and PRPP provided 
a more detailed analysis  of the nucleobases as substrates.  The kinetic 
parameters, Km and Vmax, were determined for PRTFDC1 with Hx and G 
in the forward reaction. HPRT was also characterized using this method, as 
this enzyme, to our knowledge, has never been characterized using this type 
of assay. 
The  catalytic efficiency (kcat/Km) of PRTFDC1 was 0.26%  of HPRT 
when Hx was a substrate. With G as a substrate, the catalytic efficiency of 
PRTFDC1  was 0.09% of  HPRT. For both substrates, the major 
contribution to the lower catalytic efficiencies was a marked decrease in Vmax 
(~ 70- to 310-fold). The Km values were only slightly increased (4- to 6-
fold).  
 
One  interesting feature was observed when determining the kinetic 
constants for HPRT. With Hx as a substrate, the values of Km and Vmax were 
consistent  with  earlier results. However, with G as a substrate, Km  was 
found to be 5-fold higher, and Vmax ~ 20-fold higher when determined with 
tritium-labeled substrates  as compared to the spectrophotometric assay 
(Keough et al., 1999). 
3.5  The role for residue G145 
Of the eleven conserved residues in HPRT, one residue, D137, was altered 
in PRTFDC1. As described earlier (see 3.2.1), D137 was suggested to be 
involved in catalysis. In PRTFDC1, this amino acid corresponds to G145. 
A  water molecule was observed in PRTFDC1 at the position 
corresponding to the aspartic acid side chain in HPRT. We therefore 
propose that this water molecule may act as weak base. This can also explain 
the greatly reduced Vmax-values, and relatively unchanged Km-values 
determined for PRTFDC1 with Hx and G.   
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4  Interaction profiling of FDA-approved 
nucleoside analog drugs with 23 
enzymes of human nucleotide 
metabolism (Paper III) 
4.1  Aim of the study 
This study was performed at SGC at the Karolinska Institute in Stockholm. 
At the SGC facility, one goal has been to elucidate the structures of 
enzymes  involved in nucleotide metabolism (Welin & Nordlund, 2010). 
The high throughput pipeline used for cloning, purification and structure 
determination gives a good foundation for protein production suitable in 
high throughput screening. In  this study,  the  DSLS  method has been 
applied.  
A NAL has been set up consisting of 45 FDA-approved NAs already 
used as anti-cancer agents or in treatment of viral diseases. Results obtained 
from DSLS can reveal new interactions between NAs and selected enzymes.  
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4.2  Background 
4.2.1  Selection of nucleoside analogs for the library 
In order to select the NAs that should be included in the nucleoside analog 
library, two criteria were set up:  
 
  The NAs should be approved by the FDA as pharmaceutical drugs. 
  The  structure  of the compound should include a  natural  or 
modified nucleobase, nucleoside or nucleotide.  
 
Drugbank was used as a search engine. Drugbank contains more than 
6800 drug entries, where 1431 of these are FDA-approved small molecule 
drugs (Knox et al., 2011; Wishart et al., 2008; Wishart et al., 2006). Forty-
seven NAs were identified as candidates for NAL. 
4.2.2  Nucleoside analogs 
The  45  NAs  included in NAL are  described in 1.3, and the chemical 
structures are shown in Figures 4, 5, 6 and 7. Activation mechanisms are 
illustrated in Figure 8. Adefovir is included in NAL in its prodrug form, as 
adefovir dipivoxil. Each enzyme is screened against NAL at concentrations 
of 100 and 500 µM. 
4.2.3  Enzymes investigated 
The majority  of the 23 enzymes  (Table  1)  screened  against  NAL  are 
involved in  nucleotide metabolism, described in 1.1.  One exception  is 
BPNT1, a 3´(2´),5´-bisphosphate nucleotidase, annotated as being involved 
in  sulphur  metabolism  by KEGG. However, BPNT1 catalyzes the 
hydrolysis of 3´(2´)-phosphoadenosine 5´-phosphate to AMP and inorganic 
phosphate, and is therefore included (Yenush  et al., 2000).  UMPS  is 
mentioned twice, UMPS(1) and UMPS(2), as  the domains are screened 
separately as two independent enzymes.  Furthermore, dCK was used as a 
control protein, as it is well established that this salvage enzyme plays a key 
role in the activation of several prodrugs (Eriksson et al., 2002). Human 
TK1 was intended to be used as a control protein, because of its strict 
substrate specificity. However, TK1 was discarded as a control protein due 
to the biphasic appearance of the aggregation temperature (Tagg) curve when 
analyzed by DSLS.   
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4.3  Differential Static Light Scattering  
DSLS is a high-throughput method  where  the  Tagg  of a protein is 
determined during heat-induced denaturation. The method was originally 
developed as a  screening method for identification of optimal buffer 
conditions and ligands, being able to promote enzyme stability, and 
ultimately structure determination (Vedadi et al., 2010; Senisterra & Finerty, 
2009; Senisterra et al., 2006; Vedadi et al., 2006).  
 
The theory behind protein aggregation assumes that the protein follows 
a two-state irreversible model, which is a simplified expression of the three-
state reversible-irreversible model: 
 
 
where N is the native state, and A is the aggregated state, kapp is the 
apparent rate constant, D is the denatured state, and k1, k-1 and k2 are rate 
constants (Senisterra et al., 2006). 
 
The aggregation measurements were  performed on a Stargazer 
instrument (Harbinger Biotechnology and Engineering  Corporation, 
Toronto, Canada). The protein samples in 384-well plates were placed on 
top of a heating block constructed with light-emitting diodes. The plates 
were heated from 25 to 80°C at a rate of 1°C per min. Light scattering due 
to the amount of aggregated protein, was  detected by a  charge  coupled 
device camera. Images were taken at every 0.5°C increase in temperature. 
The  increase is measured  using  a  thermistor in one well  of the plate 
(Senisterra et al., 2006).  
 
In order to calculate Tagg, the intensities (derived from each picture) can 
be plotted as a function of the temperature. Tagg  is defined as the 
temperature where at which 50% of the protein is aggregated. Addition of a 
ligand will potentially increase the stability of the enzyme, and thus raise the 
Tagg. Opinions vary on the value of ΔTagg that marks a significant increase in 
thermal stability for identifying ligands. A ΔTagg of 1.0 or 1.5°C has been 
suggested (Senisterra et al., 2006). In the work presented in this thesis, the 
cut-off for identifying a ligand is set to ΔTagg  >  1.0°C.  However, 
compounds exhibiting ΔTagg in the range 0.5 -  1°C may be tested in a  
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concentration dependent manner, in order to avoid the exclusion of 
potential ligands. 
 
Once a compound has been identified as a potential ligand,  further 
experiments such as concentration dependent stabilization in the presence of 
the potential ligand is performed. If a correlation is found, the ligand can be 
further explored using techniques such as isothermal titration calorimetry 
(ITC), enzyme assays and co-crystallisation for the further determination of 
structure  (Vedadi et al., 2010). 
  
Ligands can bind to the native and denatured protein,  giving rise to 
altered Tagg  (increased or decreased thermal shifts).  Even though some 
compounds exhibit identical thermal shifts, care should be exercised  in 
comparing results, as  the affinity  for  a ligand is  an expression of 
thermodynamic processes. When comparing thermal shifts for ligands, these 
should have similar  physicochemical  properties  (Vedadi  et al., 2010; 
Senisterra et al., 2006).  
4.4  Validation of method using dCK 
4.4.1  Background information on human dCK 
Human  dCK  catalyzes phosphorylation of the natural substrates, dCyd, 
dAdo and dGuo, with dCyd as the preferred substrate. In its active form, 
dCK is a dimer composed of two subunits (Bohman & Eriksson, 1988). 
Each subunit is comprised of 260 amino acids with a predicted mass of 30.5 
kDa  (Chottiner  et al., 1991).  The  end product,  dCTP,  acts as a strong 
feedback inhibitor (Bohman & Eriksson, 1988). Although all nucleotides 
(ATP, UTP, GTP, CTP and dTTP) can act as phosphate donors, UTP has 
been suggested to be the true intracellular phosphate donor (Hughes et al., 
1997; Krawiec et al., 1995). Depending on which donor is used, either ATP 
or UTP, the reaction mechanism can follow different pathways. With ATP 
as the phosphate donor, a rapid equilibrium, random bi-bi reaction has been 
suggested. With UTP as a phosphate donor, binding of the substrates will 
be ordered, with  UTP being the first substrate to bind before dCyd, 
followed by a random release of the products (Hughes et al., 1997; Datta et 
al., 1989).  
dCK  is responsible for the activation of a number of FDA-approved 
prodrugs e.g. lamivudine, cytarabine, cladribine, gemcitabine, fludarabine, 
zalcitabine, vidarabine,  nelarabine, decitabine, clofarabine, emtricitabine,  
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didanosine and azacitidine (Peters, 2006; Beausejour et al., 2002; Eriksson et 
al., 2002). The kinetic parameters such as Km and kcat, are given for some 
NAs if available (Table 2), with both ATP and UTP as phosphate donors. 
As  shown in Table 2, the catalytic efficiency (kcat/Km) is higher for all 
substrates/NAs where UTP is the phosphate donor. 
Table 2. Kinetic properties of dCK. Km and kcat for the natural substrates and some NAs in the presence 
of the phosphate donors, ATP and UTP. The concentration of ATP and UTP is 1 mM, except in the 
case of clofarabine, which is determined in the presence of 100 µM ATP.  
 
 
Substrates 
ATP  
Km 
(µM) 
 
kcat  
(s
-1) 
 
kcat/Km  
(M
-1 s
-1) 
UTP  
Km 
(µM) 
 
kcat  
(s
-1) 
 
kcat/Km  
(M
-1 s
-1) 
dC 
a  < 1  0.033 ± 
0.001 
> 33 × 
10
3 
< 1  0.044 ± 
0.001 
> 44 × 
10
3 
dA 
a  100 ± 20  1.7 ± 0.1  17 × 10
3  13 ± 3  0.33 ± 0.02  25 × 10
3 
dG 
a  231 ± 20  2.6 ± 0.1  11 × 10
3  21 ± 4  0.33 ± 0.02  16 × 10
3 
Zalcitabine 
b  406.8  0.18  0.4 × 10
3  N.D.  N.D.  - 
Cytarabine 
a  6.9 ± 2  0.30 ± 0.02  43 × 10
3  2.7 ± 1  0.17 ± 0.02  63 × 10
3 
Gemcitabine 
b  22.0  0.37  16.8 × 10
3  N.D.  N.D.  - 
Emtricitabine 
c  4.4 ± 
0.6 
0.036 ± 
0.001 
8.2 × 10
3  6.2 ± 
0.5 
0.100 ± 
0.002 
16.2 × 10
3 
Lamivudine 
d  3.4 ± 
1.0 
0.030 ± 
0.001 
8.8 × 10
3  8.0 ± 
1.0 
0.102 ± 
0.001 
12.8 × 10
3 
Cladribine 
e  78 ± 16  0.6 ± 0.04  7.7 × 10
3  5.1 ± 
0.9 
0.37 ± 0.01  72.6 × 10
3 
Clofarabine 
f  3.3 ± 
0.6 
N.D.  -  N.D.  N.D.  - 
a (Godsey et al., 2006), b (Sabini et al., 2003), c (Sabini et al., 2007b), d (Sabini et al., 2007a), 
e (Sabini et al., 2008a), f (Lotfi et al., 1999). N.D. – Not determined. 
 
Sabini et al. determined the structure of human dCK in complex with 
dCyd as well as two NAs; gemcitabine and cytarabine (Sabini et al., 2003). 
Since then, a wealth of information about binding of natural substrates and 
NAs in the presence or absence of phosphate donors has been gathered 
(Hazra et al., 2010; Sabini et al., 2008a; Sabini et al., 2008b; Sabini et al., 
2007a; Sabini et al., 2007b; Godsey et al., 2006; Zhang et al., 2006).  
4.4.2  Detailed view of dCK in complex with substrates  
The complexes used for the analysis of the binding of substrates and NAs in 
the active site of dCK were dCyd-ADP (Sabini et al., 2003), clofarabine-
ADP (Zhang et al., 2006) and lamivudine-ADP (Sabini et al., 2007a), as  
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representatives of a natural pyrimidine substrate, a purine NA and an L-
nucleoside analog, respectively (Figure 12).  
 
Figure 12. Active site of dCK with dCyd (grey), clofarabine (green) and lamivudine (yellow). 
Hydrogen bonds are shown for dCK with dCyd.  
The main interactions for dCyd are with Q97, D133, Y86, E197 and 
indirectly to Y204 through a water molecule. E53 and R128 have been 
suggested to act as a catalytic couple, where R128 anchors the position of 
E53, so that this glutamate can act as a base (Sabini et al., 2003; Eriksson et 
al., 2002). With clofarabine bound in the active site, Q97 has moved to 
accommodate room for the bigger purine base. The 3’-OH of clofarabine is 
kept in the same position, while the position of 5’-OH together with E53 
has moved. The fluorine group at the 2’-position of clofarabine forms a 
hydrogen bond with  R128  (Zhang  et al., 2006). The cytosine  base of 
lamivudine binds in the same way as dCyd, however the base is tilted by  
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10°. A structural water molecule is found in the lamivudine  structure, 
creating hydrogen bonds to E197 and Y86. In order to position the 5’-OH 
of lamivudine correctly  for a nucleophilic attack from E53, the five-
membered ring is rotated ~ 30° around the glycosidic bond (Sabini et al., 
2007a). This illustrates the plasticity of the active site of dCK, and explains 
the promiscuous nature of dCK. 
4.4.3  DSLS screening of dCK  
Metabolome library screen 
In order to evaluate dCK as a model protein, the metabolome library screen 
described in 3.4.1 was used, and the results are shown in Table 3 in Paper 
III. The fingerprint of the dCK metabolome thermal shifts correlated well 
with  what is known about dCK, thus supporting the use of DSLS for 
identification of biologically  relevant interactions.  The distal feedback 
inhibitor, dCTP, induced a positive thermal shift of 16°C for dCK. The 
natural products are represented by dCMP (ΔTagg = 11.9°C), dGMP (ΔTagg 
= 3.3°C) and dAMP (ΔTagg = 1.5°C). Of the phosphate donors, ATP was 
shown to give a decreased Tagg for dCK, while UTP stabilized the protein 
with a ΔTagg of 1.4°C. An interesting observation was that both dADP and 
dGDP stabilized the protein more effectively than their corresponding 
triphosphate forms.   
NAL 
The control protein,  dCK,  was screened against  NAL at  different 
concentrations (100 and 500 µM) and at 500 µM NAL in the presence of 
0.1 and 1 mM ATP.  The results are shown in Table  2  in  Paper III. 
Emtricitabine, lamivudine, decitabine, clofarabine, cladribine, gemcitabine, 
cytarabine and fludarabine were identified as ligands, both in the absence 
and presence of ATP, but with higher thermal shifts in the presence of 1 
mM ATP (~ 5 to 10°C). It is important to note that cladribine was not 
identified as a ligand in the absence of ATP, and that fludarabine was only 
identified as a ligand in the absence of ATP.  
All identified ligands, with exception of fludarabine, exhibited positive 
concentration-dependent  stabilization of dCK, while fludarabine induced 
negative concentration-dependent stabilization going from a ΔTagg around 
2°C at 100 µM to just below 0°C at 1000 µM fludarabine. Furthermore, 
dCK has been co-crystallized with almost all identified ligands in this group, 
with the two exceptions of decitabine and fludarabine. 
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A second group of compounds were revealed when 1 mM ATP was 
added to dCK when screening. This group appeared directly after the top 
thermal shifts, with ΔTagg values in the range of 0.5 to 1.0°C, but with 
relative thermal shifts above 1°C after addition of ATP. This group 
consisted of zalcitabine, entecavir, azacitidine, vidarabine and nelarabine. As 
it is established from the literature that several of these NAs (zalcitabine, 
vidarabine, azacitidine and nelarabine) are ligands of dCK, it is possible that 
the detection limit could be set at 0.5°C instead of 1.0°C for dCK after 
repeated tests. 
 
 As  a  general rule,  interactions  between dCK and emtricitabine, 
lamivudine, decitabine, clofarabine, cladribine, gemcicitabine, cytarabine 
and  fludarabine  are revealed even in the absence of ATP.  Interactions 
between  dCK and zalcitabine, entecavir, azacitidine, vidarabine and 
nelarabine are revealed only in the presence of 1 mM ATP, but below the 
set detection limit at 1.0.  This group of NAs  would not have been 
identified without the addition of ATP.  
 
In total, eight ligands were identified as ligands for dCK, while a 
subgroup appeared with a ΔTagg in the range 0.5 to 1.0°C. However, it is 
important  to include this subgroup as  ligands. All  reported interactions 
between dCK and NAs in NAL, with the exception of didanosine, were 
thus detected. In addition, an interaction between dCK and entecavir was 
detected.  
 
It is possible that the thermal shifts were greater when ATP was added 
due to the formation of the products or because the two substrates together 
led to the formation of a more stable enzyme. However, had dCK and 
NAL not been screened in the presence of ATP, only eight ligands would 
have been detected.  
4.5  Results 
The results for all 23 enzymes screened against 500 µM NAL are shown in 
Figure 13. Tagg for each enzyme is listed in Table 1. Focused follow-up 
studies were performed on three enzymes; UPP1, GDA and RRM1. 
4.5.1  Uridine phosphorylase 1  
UPP1 catalyzes the reversible reaction of the conversion of uridine  and 
inorganic phosphate into uracil and ribose-1-phosphate  (Renck  et al.,  
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The interaction between UPP1 and vidarabine was highly unexpected, 
with an elevated thermal shift of ~ 8°C. Trifluridine and idoxuridine 
exhibited thermal shifts in the range of 4 to 5°C, which is slightly elevated 
compared to uridine, the natural substrate. Zidovudine, telbivudine, 
fluorouracil, floxuridine and thioguanine all exhibited positive thermal shifts 
in the range of 1.7 to 2.4°C. All reported values are obtained in the 
presence of 1 mM compound, and data is obtained from concentration-
dependent stabilization curves in the presence of 1 mM compound. 
Two NAs, fluorouracil and floxuridine, have been reported to be 
substrates for UPP1  (Cao  et al., 2002). To our knowledge,  interactions 
between UPP1 and vidarabine, idoxuridine, trifluridine, telbivudine, 
zidovudine and thioguanine have never been reported before. The fact that 
zidovudine was identified as a ligand was interesting. In a study by Calabresi 
et al.  in 1990, reduced zidovudine-derived bone marrow toxicity was 
observed when mice were given benzylacyclouridine, an inhibitor of UPP1. 
This effect was explained by elevated levels of uridine  (Calabresi  et al., 
1990). It is tempting to speculate whether  zidovudine is a substrate of 
UPP1,  and  if the observed bone marrow toxicity could be caused by 
zidovudine metabolites.   
4.5.2  Guanine deaminase 
GDA catalyzes the irreversible reaction in which guanine is deaminated to 
become xanthine (Yuan et al., 1999). Six ligands were identified and these 
could be separated into two groups. The first group,  containing the 
mercaptopurine derivatives consisted of mercaptopurine and thioguanine. 
The second group,  containing acyclic guanine derivatives consisted of 
valaciclovir, aciclovir, penciclovir and ganciclovir. The results are shown in 
Figures 2B and 4 in Paper III. 
 
Valaciclovir stabilized GDA with a positive thermal shift ~ 7.2°C, a shift 
similar to that for  the natural substrate,  guanine.  Valaciclovir can be 
regarded as a ligand of GDA, as the structure of GDA was solved with 
valaciclovir bound in the active site. This is further discussed in Paper III. 
 
The effect of different functional groups can be compared within the 
two groups. The only difference between thioguanine and mercaptopurine 
is the amino group at the 2-position in thioguanine. The thermal shift for 
thioguanine is ~ 4.3°C  at 1 mM, which is 3.3°C  higher than for 
mercaptopurine, indicating the importance of this amino group. Within the 
second group for acyclic guanine derivatives, it is evident that the longer  
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chains found in a compound such as valaciclovir establish a higher thermal 
shift compared to aciclovir (~ 4.2°C). Branched chains at the 9-position of 
the purine ring e.g. in penciclovir and ganciclovir, stabilized GDA with 
thermal shifts between 1.1 and 2.3°C.  
 
Thioguanine is the only ligand which has been described as a weak 
substrate for GDA isolated from rabbit liver and pig brain (Bergstrom & 
Bieber, 1979; Rossi et al., 1978). We have determined that valaciclovir is a 
ligand of GDA by structure determination. For the other ligands, aciclovir, 
penciclovir, ganciclovir and mercaptopurine, as well as valaciclovir, further 
experiments  will be required  to determine the nature of the ligand. 
However, these results can serve as a platform for a focused study for the 
identification of new improved ligands of GDA. 
4.5.3  Ribonucleotide reductase with azathioprine 
RRM1, which is the large subunit (R1) of ribonucleotide reductase, was 
destabilized in the presence of azathioprine in a dose dependent manner. 
The result is shown in Figure 2C in Paper III. Azathioprine is a prodrug of 
mercaptopurine. It contains a substituted imidazole ring attached the 6-thio 
group of a purine ring (Figure 7). Mercaptopurine by itself only destabilizes 
RRM1 with a slightly negative thermal shift.  
One possible explanation for the negative thermal shifts for RRM1 in 
the presence of azathioprine is  that this compound binds to either the 
catalytic site or the specificity site of RRM1. With the large imidazole ring 
at the 6-position, azathioprine is able to destabilize RRM1. Further work is 
needed to substantiate this hypothesis.    
4.6  AlFx – attempts to generate a phosphorylated NAL mimic  
In the search for interactions between NAs and cellular enzymes, the NAL 
should ideally consist of NAMPs, NADPs and NATPs. This may provide 
an alternative way to identify new interactions.  
 
Aluminofluoride (AlFx) and beryllofluoride (BeFx)  have  been used as 
phosphate analogs. AlFx can exist in several complexed states, where x can 
be between 1 and 6, and AlF4
- represents the tetrahedral analog (Strunecka 
et  al., 2002; Chabre, 1990).  In order to generate  a  mimic of a 
phosphorylated NAL we  attempted to use  AlFx  alone and in  different 
combinations with pyrophosphate (PPi) and/or free phosphate ions. Once 
again, dCK was used as a control protein. AlFx alone, however, did not  
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stabilize the enzyme in the presence of known ligands (dCyd, emtricitabine 
and lamivudine). Interestingly, PPi alone was able to stabilize dCK in the 
presence of the  known ligands. AlFx  alone was tested on the two 5’-
nucleotidases, NT5C2 and NT5C3, that had previously been crystallized in 
the presence of AlFx and/or BeF3 (Wallden et al., 2007; Bitto et al., 2006). 
The result for NT5C2 did show an elevated thermal shift of 8.8°C in the 
presence of AlFx (1 mM AlCl3 + 10 mM NaF), although this did not reveal 
any extra NA interactions for NT5C2. For NT5C3, an increased thermal 
shift of 1.7°C was observed in the presence of AlFx, but no additional NAs 
were identified. Altogether, these results indicate that the addition of AlFx 
was not a reliable way to generate a mimic of a NAL for the kinases.  
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5  Conclusions and future perspectives 
In this thesis, some of the enzymes involved in nucleotide metabolism have 
been studied.  Focused studies have been performed on  two enzymes  in 
particular; UMPK from Ureaplasma parvum  and  PRTFDC1,  a human 
homolog of HPRT. Furthermore, a nucleoside analog library was created 
and screened with 23 enzymes within this pathway. 
5.1  Ureaplasma parvum UMPK 
The structure of  Up-UMPK was determined, and showed a hexameric 
enzyme belonging to the amino acid kinase family. Interactions between 
Up-UMPK and its natural substrates were characterized, revealing a high Km 
value for UMP. The idea was to investigate Up-UMPK as a potential target 
enzyme for antibiotic  development.  It is unlikely  that  chemical 
modifications of UMP could generate substrates for Up-UMPK with lower 
Km values. We propose, therefore, that if Up-UMPK is still viewed as a 
potential antibiotic target, non-nucleosides/non-nucleotides should be 
considered as potential inhibitors. An interesting finding about Up-UMPK 
was that this enzyme, in contrast to other bacterial UMPKs, is not activated 
by GTP. Amino acid residues in a region between α-helix 3 and β-strand 5 
have been shown in other UMPKs to be responsible for binding GTP. In 
many cases, arginines are responsible for interaction with GTP, and in Up-
UMPK there are no arginines in this region, which most likely explains the 
lack of GTP-activation. Archaeal UMPKs have also been shown to lack the 
ability  to be  activated by GTP. The physiological role for this lack of 
allosteric regulation in archaeal and mollicute UMPKs may be related to an 
altered role of GTP in these organisms compared to other major phyla.  
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5.2  PRTFDC1 
PRTFDC1 was reported to be a homolog of HPRT, but the function of 
the protein was listed as unknown. The structure of PRTFDC1 was 
determined with GMP in the active site, which showed a fold similar to 
HPRT. Using a nucleotide metabolome screen, ligands were identified. In 
accordance with substrates and products for HPRT, Hx, G PRPP, IMP and 
GMP were identified as ligands. In order to investigate if PRTFDC1 had 
any enzymatic activity toward  these potential  substrates, a radiochemical 
assay revealed that both Hx and G could be converted into their products.  
However the activity of PRTFDC1 when compared to HPRT was only 
0.26% for Hx and 0.09% for G. The presence of G145 in the position of 
D137 of HPRT, could explain this low catalytic efficiency. A mutational 
study involving the conversion of residue G145 into D145 in PRTFDC1 
would clarify this hypothesis. 
Mutations in all regions of HPRT1, however, have been shown to alter the 
kinetic properties significantly, and as sequence identity is 65%, alterations 
in other regions could also account for the differences.  
 
An interesting observation in our study was that the Vmax value obtained 
for HPRT with G as a substrate was 20-fold higher than earlier published 
results. This discrepancy possibly depends on the different assays used in this 
and previous studies. 
 
Many  questions  remain  regarding the function of PRTFDC1. Does 
PRTFDC1 play a role in patients with partial or full HPRT deficiencies, by 
changing the phenotype of the specific HPRT genotype? Or, is PRTFDC1 
a potential tumor suppressor gene, as reported in two studies? Finally, does 
PRTFDC1 interact with HPRT, and in this way affect HPRT activity? 
Further studies are needed to answer these questions, but molecular genetic 
screening of patients with Lesch-Nyhan phenotype may reveal if 
compensatory mutations in PRTFDC1 play a role in the disease.  
5.3  Nucleoside analog library 
A NAL has been set up consisting of 45 FDA-approved NAs. This has been 
screened using DSLS with 23 enzymes involved in nucleotide metabolism. 
Only a few  cross-reactivities were observed  between  these enzymes and 
NAs, which demonstrates that the NAs are specific for their putative drug 
target.  
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In order to validate the method, the well-characterized salvage enzyme, 
dCK, was used. Eight interactions between dCK and NAs were identified 
with thermal shifts above the set detection limit; another five NAs appeared 
to be potential  ligands  when 1 mM ATP was added to the screen. 
Altogether, almost all ligands of dCK were identified using DSLS.  
 
When screening UPP1 and GDA, several NAs gave rise to elevated 
thermal shifts. Vidarabine, trifluridine, idoxuridine, zidovudine, telbivudine, 
fluorouracil, floxuridine and thioguanine were all identified as ligands of 
UPP1. The most unexpected interaction seen for UPP1 was with 
vidarabine, an adenine analog. Several ligands were identified for GDA; 
these were valaciclovir, aciclovir, penciclovir, ganciclovir, thioguanine and 
mercaptopurine. Furthermore, the structure of GDA co-crystallized with 
valaciclovir was solved, confirming that this was a true ligand. A negative 
concentration-dependent stabilization was observed for RRM1 with 
azathioprine. This suggests that azathioprine binds to sites within RRM1, 
and thus destabilizes the enzyme.   
 
This study serves as an initial screen for the identification of potential 
ligands. The positive concentration-dependent stabilization curves indicate 
that these compounds are indeed ligands. However, before these ligands can 
be classified either as substrates, inhibitors or activators, further experiments 
will have to be performed. 
 
UPP1 and GDA bind  nucleosides/nucleobases and nucleobases, 
respectively. It is thus not surprising that it was possible to identify new or 
well known ligands for these enzymes, as the NAs are primarily found as 
either nucleosides or nucleobases in NAL. Some  interactions between 
selected enzymes and some phosphorylated forms of the NAs have almost 
certainly been missed.  
 
This sheds light on the importance of having all forms of every NA (i.e. 
NA, NAMP, NADP and NATP) in the library, in order to reveal the 
complete map of interactions between the NAL and a target enzyme.   
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